<DOC>
<DOCNO>
EP-0011111
</DOCNO>
<TEXT>
<DATE>
19800528
</DATE>
<IPC-CLASSIFICATIONS>
A61P-19/00 A61P-37/00 C07D-513/00 A61P-29/00 C07D-513/04 C07D-213/00 A61K-31/425 A61K-31/4427 C07D-213/50 <main>C07D-513/04</main> A61K-31/4188 A61K-31/429 A61K-31/4164 A61P-19/02 A61P-37/02 
</IPC-CLASSIFICATIONS>
<TITLE>
5-(4-pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition.
</TITLE>
<APPLICANT>
smithkline corpus<sep>smithkline corporation<sep>smithkline beckman corporationp.o. box 7929 1 franklin plazaphiladelphia pennsylvania 19101us<sep>smithkline beckman corporation <sep>
</APPLICANT>
<INVENTOR>
bender paul elliot<sep>lantos ivan<sep>bender, paul elliot<sep>lantos, ivan<sep>bender, paul elliot504 lilac lanecherry hill, new jersey 08003us<sep>lantos, ivan1447 boxwood driveblackwood, new jersey 08012us<sep>bender, paul elliot<sep>lantos, ivan<sep>bender, paul elliot504 lilac lanecherry hill, new jersey 08003us<sep>lantos, ivan1447 boxwood driveblackwood, new jersey 08012us<sep>
</INVENTOR>
<ABSTRACT>
5(4-pyridyl)-6(4-fluorophenyl)-2,3-dihydroimidazo  -[2,1-b] thiazole has significant antiarthritic and immuno­ regulatory activity compared with its 5,6-transposed isomer.   the compound is prepared by reacting 4-(4-pyridyl-­ 5-[4-fluorophenyl) -2-mercaptoimidazole with a reactive  ethylene dihalide then separating the isomeric mixture of  products.  
</ABSTRACT>
</TEXT>
</DOC>
